
Voltron Therapeutics: Specializing in precision-guided vaccines for cancer and infectious diseases.
Voltron Therapeutics, founded as a Delaware corporation, focuses on developing precision-guided, self-assembling vaccines aimed at enhancing cell-mediated responses to combat cancer and infectious diseases, including COVID-19. Utilizing the proprietary VaxCelerate™ Self-Assembling Vaccine Design, developed by specialists at Massachusetts General Hospital (MGH) and the Vaccine & Immunotherapy Center, Voltron Therapeutics aims to revolutionize vaccine development and improve public health outcomes.
Notable affiliations include an exclusive licensing agreement with Massachusetts General Hospital for the VaxCelerate™ technology. Key achievements include significant advancements in vaccine design and development, particularly in addressing urgent health threats like COVID-19. Voltron Therapeutics' impact is marked by its innovative approach to vaccine creation, potentially offering more effective and targeted immunization solutions for some of the most challenging diseases.

VLP Therapeutics

VitriVax
vitrivaxbio.com

Virion Therapeutics
viriontx.com

VaxEquity

Volastra Therapeutics
volastratx.com

Innovac Therapeutics
innovactx.com

CellVax Therapeutics
cellvx.com
Attivare Therapeutics

Vaxxinity
vaxxinity.com

Calder Biosciences

Solaris Vaccines
solarisvax.com

X-Vax Technology

Vaccinex
vaccinex.com

Thyreos

Vivaldi Biosciences
Companies similar to Voltron Therapeutics include VLP Therapeutics, VitriVax, Virion Therapeutics and VaxEquity.
Voltron Therapeutics was founded in 2017.
Voltron Therapeutics' headquarters is located in New York City, NY, US.
Voltron Therapeutics' most recent funding round was for $5.9M (USD) in August 2023.
As of Aug 17, 2023, Voltron Therapeutics has raised a total of $5.9M (USD).
Voltron Therapeutics has 9 employees as of Feb 5, 2024.